About Hememics Biotechnologies
Hememics Biotechnologies is a Technology company based in Gaithersburg (United States) founded in 2009 by David Huy Ho and John L Warden. Biopreservation platform for mammalian cells and biologics is developed. It operates in the Technology and Healthcare sectors. Hememics Biotechnologies has raised $4.6 million across 5 funding rounds from investors including HHS, TEDCO and American Vietnamese Investment Partners. The company has 13 employees. Its chief executive, as recorded, is John L Warden. Hememics Biotechnologies offers products and services including HemBox, Hem Chip Reader, and Biochip. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Biosensors. Its legal entity is Hememics Biotechnologies, Inc. Its competitors include DermaSensor, Zerigo Health and Cardea Bio; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2009 and headquartered in Gaithersburg, United States, HeMemics Biotechnologies operates in the biotechnology sector focused on biopreservation. Patented HeMeDri technology is utilized to create preservation solutions such as HemSol, which enable storage of mammalian cells and perishable biologics in desiccated or non-desiccated forms at cold or ambient temperatures. Customized stabilization services are provided for proteins, cells, and tissues in dried or non-dried formats to facilitate storage and transport.
- Headquarters Gaithersburg, United States
- Employees 13
- Founders David Huy Ho, John L Warden
- SectorsTechnologyHealthcare
- Email••••••••
- Phone•••• ••••
- Website hememics.com
- Social LinkedIn X
- Legal Name Hememics Biotechnologies, Inc.
- Total Equity Funding$4.6M (USD)
in 5 rounds
- Latest Funding Round$2M (USD), Seed
May 2023
- InvestorsHHS
& 2 more
- Employee Count13
Products & Services of Hememics Biotechnologies
Hememics Biotechnologies offers a comprehensive portfolio of products and services, including HemBox, Hem Chip Reader, and Biochip.
Handheld device for rapid detection of substances in various fields
Reader for accurate biochip results in testing applications
Multiplexed chip for simultaneous detection of multiple targets
Funding Insights of Hememics Biotechnologies
Hememics Biotechnologies has successfully raised a total of $4.6M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $2 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.6M
- Total Rounds 5
- Last Round Seed — $2M
- First Round $185,480
(Jul 2012)
- Investors Count 3
All 5 funding rounds of Hememics Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $2M | Seed | – | – | |
| Dec 2020 | $100,000 | Seed | – | – | – |
| Dec 2019 | $2.5M | Seed | – | American Vietnamese Investment Partners | – |
| Apr 2018 | Seed | – | – | – | |
| Jul 2012 | $185,480 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Hememics Biotechnologies
Hememics Biotechnologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, TEDCO and American Vietnamese Investment Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund and startup accelerator programs focused on seed and early stage companies | 1998 | tedcomd.com | Columbia, United States | |
| amvipartners.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Hememics Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hememics Biotechnologies
6 people are tracked at Hememics Biotechnologies (6 in leadership); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
David Huy Ho | Co-Founder | Leadership |
John L Warden | Co-Founder & CEO | Leadership |
John L. Warden, Jr. | Co-Founder & CEO | Leadership |
Richard Liu | CFO | Leadership |
Srivatsa Aithal (Sri) | Director Of R&d | Leadership |
Thomas S. Dann | Director | Leadership |
Complete people profiles for Hememics Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Hememics Biotechnologies
3 dated milestones of Hememics Biotechnologies across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Hememics Biotechnologies is founded.
- Funding First funding round of $185K.
- Funding Latest funding round, Seed, of $2.0M.
Competitors of Hememics Biotechnologies
Hememics Biotechnologies has 3 listed competitors in our database, 3 of them funded. They include DermaSensor, Zerigo Health and Cardea Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dermasensor.com | 2009 | Miami, United States | $60.75M | 13 | Handheld diagnostic device for skin cancer lesions is developed. | |
| zerigohealth.com | 2014 | San Diego, United States | $77.92M | Developer of UVB light therapy devices for monitoring Psoriasis, Vitiligo, and Eczema | ||
| cardeabio.com | 2019 | San Diego, United States | $21.8M | Digital graphene biosensors are developed using machine learning. |
Detailed competitors of Hememics Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Hememics Biotechnologies
Websites that share an audience with Hememics Biotechnologies (hememics.com).
Websites whose visitors overlap most with Hememics Biotechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Sensors & Smart Devices
3 companies that operate in the same segment as Hememics Biotechnologies (Sensors & Smart Devices) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Smart fitness equipment and streaming platforms are provided. | 2011 | New York, New York, United States | USD 995.53 M | USD 2.45 B | 2,894 | |
VR-based head-mounted displays for gaming are provided by Oculus. | 2012 | Menlo Park, California, United States | USD 107.05 M | |||
Cloud-based business telephony and home security services are provided. | 2004 | Palo Alto, California, United States | USD 87.97 M | USD 273.6 M | 1,190 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hememics Biotechnologies
Complete news archive for Hememics Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hememics Biotechnologies
Hememics Biotechnologies was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Hememics Biotechnologies is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
John L Warden is the CEO of Hememics Biotechnologies, as recorded in our data. They have also founded this company.
Hememics Biotechnologies is a funded company, having raised a total of $4.6M across 5 funding rounds to date. The company's 1st funding round was a Grant of $185.48K, raised on Jul 2012.
Hememics Biotechnologies has 13 employees.
Founded in 2009 and headquartered in Gaithersburg, United States, HeMemics Biotechnologies operates in the biotechnology sector focused on biopreservation. Patented HeMeDri technology is utilized to create preservation solutions such as HemSol, which enable storage of mammalian cells and perishable biologics in desiccated or non-desiccated forms at cold or ambient temperatures. Customized stabilization services are provided for proteins, cells, and tissues in dried or non-dried formats to facilitate storage and transport.
Hememics Biotechnologies's top competitors include DermaSensor, Cardea Bio and Zerigo Health.
Hememics Biotechnologies offers HemBox, Hem Chip Reader, and Biochip.
Hememics Biotechnologies operates through Hememics Biotechnologies, Inc..